Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOSTON, June 26, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, will be presenting clinical data for its leading drug candidate, TI-001, intranasal oxytocin, for the treatment of chronic migraine at the 2013 International Headache Congress (IHC), hosted by the International Headache Society and American Headache Society, June 27th-30th, 2013, in Boston, Massachusetts.
Help employers find you! Check out all the jobs and post your resume.
